A new clinical trial has confirmed that the weight loss drug Ozempic, which contains the active ingredient semaglutide, significantly reduces alcohol cravings in users. This unexpected effect has been reported by thousands of users, who have found themselves losing interest in alcohol, gambling, compulsive shopping, and other addictive behaviors after starting the medication. The drug works by mimicking a hormone called GLP-1 in the brain, which influences dopamine pathways in areas that control reward and pleasure.

Research has shown that Ozempic not only reduces food cravings but also dampens cravings for addictive substances, making it a potential treatment for alcohol use disorder. While not everyone experiences these effects and the drug carries risks, Phase 3 trials are currently underway to evaluate the use of GLP-1 drugs like semaglutide for addiction treatment, which could potentially transform how alcohol use disorder is managed in the future.